BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38237862)

  • 1. The breast cancer coagulome in the tumor microenvironment and its role in prognosis and treatment response to chemotherapy.
    Tinholt M; Tekpli X; Torland LA; Tahiri A; Geisler J; Kristensen V; Sandset PM; Iversen N
    J Thromb Haemost; 2024 May; 22(5):1319-1335. PubMed ID: 38237862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coagulation factor V in breast cancer: a p53-regulated tumor suppressor and predictive marker for treatment response to chemotherapy.
    Lind SM; Sletten M; Hellenes M; Mathelier A; Tekpli X; Tinholt M; Iversen N
    J Thromb Haemost; 2024 Jun; 22(6):1569-1582. PubMed ID: 38382738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pan-cancer analysis of the human tumor coagulome and its link to the tumor immune microenvironment.
    Saidak Z; Soudet S; Lottin M; Salle V; Sevestre MA; Clatot F; Galmiche A
    Cancer Immunol Immunother; 2021 Apr; 70(4):923-933. PubMed ID: 33057845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The tumor immune microenvironment and immune-related signature predict the chemotherapy response in patients with osteosarcoma.
    He L; Yang H; Huang J
    BMC Cancer; 2021 May; 21(1):581. PubMed ID: 34016089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer.
    Tabchy A; Valero V; Vidaurre T; Lluch A; Gomez H; Martin M; Qi Y; Barajas-Figueroa LJ; Souchon E; Coutant C; Doimi FD; Ibrahim NK; Gong Y; Hortobagyi GN; Hess KR; Symmans WF; Pusztai L
    Clin Cancer Res; 2010 Nov; 16(21):5351-61. PubMed ID: 20829329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Genes with Prognostic Value in the Breast Cancer Microenvironment Using Bioinformatics Analysis.
    Ren H; Hu D; Mao Y; Su X
    Med Sci Monit; 2020 Apr; 26():e920212. PubMed ID: 32251269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis.
    Abdel-Fatah TMA; Agarwal D; Liu DX; Russell R; Rueda OM; Liu K; Xu B; Moseley PM; Green AR; Pockley AG; Rees RC; Caldas C; Ellis IO; Ball GR; Chan SYT
    Lancet Oncol; 2016 Jul; 17(7):1004-1018. PubMed ID: 27312051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioinformatic profiling of prognosis-related genes in the breast cancer immune microenvironment.
    Bai F; Jin Y; Zhang P; Chen H; Fu Y; Zhang M; Weng Z; Wu K
    Aging (Albany NY); 2019 Nov; 11(21):9328-9347. PubMed ID: 31715586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mining immune-related genes with prognostic value in the tumor microenvironment of breast invasive ductal carcinoma.
    He Q; Xue S; Wa Q; He M; Feng S; Chen Z; Chen W; Luo X
    Medicine (Baltimore); 2021 Apr; 100(17):e25715. PubMed ID: 33907159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishment and validation of an aging-related risk signature associated with prognosis and tumor immune microenvironment in breast cancer.
    Wang Z; Liu H; Gong Y; Cheng Y
    Eur J Med Res; 2022 Dec; 27(1):317. PubMed ID: 36581948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unfolded protein response signature unveils novel insights into breast cancer prognosis and tumor microenvironment.
    Zhou N; Kong D; Lin Q; Yang X; Zhou D; Lou L; Huang F
    Cancer Genet; 2023 Aug; 276-277():17-29. PubMed ID: 37343507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Five-Gene Signature Based on Stromal/Immune Scores in the Tumor Microenvironment and Its Clinical Implications for Liver Cancer.
    Liu X; Niu X; Qiu Z
    DNA Cell Biol; 2020 Sep; 39(9):1621-1638. PubMed ID: 32758021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a novel immune-related prognostic signature associated with tumor microenvironment for breast cancer.
    Ding S; Sun X; Zhu L; Li Y; Chen W; Shen K
    Int Immunopharmacol; 2021 Nov; 100():108122. PubMed ID: 34536743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An immune-related risk gene signature predicts the prognosis of breast cancer.
    Cao W; Jiang Y; Ji X; Ma L
    Breast Cancer; 2021 May; 28(3):653-663. PubMed ID: 33400208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An immune cell infiltration-based immune score model predicts prognosis and chemotherapy effects in breast cancer.
    Sui S; An X; Xu C; Li Z; Hua Y; Huang G; Sui S; Long Q; Sui Y; Xiong Y; Ntim M; Guo W; Chen M; Deng W; Xiao X; Li M
    Theranostics; 2020; 10(26):11938-11949. PubMed ID: 33204321
    [No Abstract]   [Full Text] [Related]  

  • 16. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
    Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
    Front Immunol; 2022; 13():891175. PubMed ID: 35990668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of stromal ColXα1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancer.
    Brodsky AS; Xiong J; Yang D; Schorl C; Fenton MA; Graves TA; Sikov WM; Resnick MB; Wang Y
    BMC Cancer; 2016 Apr; 16():274. PubMed ID: 27090210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring immune-related genes with prognostic value in microenvironment of breast cancer from TCGA database.
    Yang H; Zhao K; Kang H; Wang M; Wu A
    Medicine (Baltimore); 2020 Apr; 99(14):e19561. PubMed ID: 32243373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
    Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C
    World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.
    Lyu X; Wang P; Qiao Q; Jiang Y
    BMC Cancer; 2021 May; 21(1):646. PubMed ID: 34059019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.